Long-Acting Injectable GLP-1 Receptor Agonists for the Treatment of Adults with Type 2 Diabetes: Perspectives from Clinical Practice
Mario Luca Morieri, Angelo Avogaro, Gian Paolo Fadini Department of Medicine, University of Padova, Padova 35128, ItalyCorrespondence: Mario Luca MorieriDepartment of Medicine, University of Padova, Via Giustiniani 2, Padova 35128, ItalyTel +39 049 8217094Email morieri.mL@gmail.comAbstract: Randomiz...
Guardado en:
Autores principales: | Morieri ML, Avogaro A, Fadini GP |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/dc598af776a743eeb3d537f5ebd78e23 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Cardiovascular outcomes after initiating GLP-1 receptor agonist or basal insulin for the routine treatment of type 2 diabetes: a region-wide retrospective study
por: Enrico Longato, et al.
Publicado: (2021) -
Role and development of GLP-1 receptor agonists in the management of diabetes
por: Chee W Chia, et al.
Publicado: (2009) -
Emerging role of GLP-1 receptor agonists in the treatment of obesity
por: Lisa M Neff, et al.
Publicado: (2010) -
Neurocranial Morphology of the Albanian Kosovo Population
por: Rexhepi,Agron M, et al.
Publicado: (2014) -
Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in Germany
por: Andreas Straube, et al.
Publicado: (2021)